GSK vs. DPH, AZN, HLN, SN, CTEC, HIK, MDC, BTG, ABC, and UDG
Should you be buying GSK stock or one of its competitors? The main competitors of GSK include Dechra Pharmaceuticals (DPH), AstraZeneca (AZN), Haleon (HLN), Smith & Nephew (SN), ConvaTec Group (CTEC), Hikma Pharmaceuticals (HIK), Mediclinic International (MDC), BTG (BTG), Abcam (ABC), and UDG Healthcare (UDG). These companies are all part of the "medical" sector.
GSK (LON:GSK) and Dechra Pharmaceuticals (LON:DPH) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their community ranking, media sentiment, earnings, analyst recommendations, dividends, valuation, institutional ownership, profitability and risk.
GSK has a net margin of 14.59% compared to Dechra Pharmaceuticals' net margin of -3.66%. GSK's return on equity of 38.78% beat Dechra Pharmaceuticals' return on equity.
44.8% of GSK shares are held by institutional investors. Comparatively, 105.5% of Dechra Pharmaceuticals shares are held by institutional investors. 1.6% of GSK shares are held by insiders. Comparatively, 9.3% of Dechra Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
GSK pays an annual dividend of GBX 60 per share and has a dividend yield of 3.4%. Dechra Pharmaceuticals pays an annual dividend of GBX 45 per share and has a dividend yield of 1.2%. GSK pays out 5,504.6% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Dechra Pharmaceuticals pays out -18,000.0% of its earnings in the form of a dividend.
GSK has a beta of 0.27, meaning that its share price is 73% less volatile than the S&P 500. Comparatively, Dechra Pharmaceuticals has a beta of 0.78, meaning that its share price is 22% less volatile than the S&P 500.
In the previous week, GSK had 2 more articles in the media than Dechra Pharmaceuticals. MarketBeat recorded 2 mentions for GSK and 0 mentions for Dechra Pharmaceuticals. GSK's average media sentiment score of 0.28 beat Dechra Pharmaceuticals' score of 0.00 indicating that GSK is being referred to more favorably in the media.
GSK received 732 more outperform votes than Dechra Pharmaceuticals when rated by MarketBeat users. However, 63.00% of users gave Dechra Pharmaceuticals an outperform vote while only 50.19% of users gave GSK an outperform vote.
GSK has higher revenue and earnings than Dechra Pharmaceuticals. Dechra Pharmaceuticals is trading at a lower price-to-earnings ratio than GSK, indicating that it is currently the more affordable of the two stocks.
GSK presently has a consensus price target of GBX 1,675.63, suggesting a potential downside of 5.14%. Given GSK's higher probable upside, equities research analysts plainly believe GSK is more favorable than Dechra Pharmaceuticals.
Summary
GSK beats Dechra Pharmaceuticals on 13 of the 19 factors compared between the two stocks.
Get GSK News Delivered to You Automatically
Sign up to receive the latest news and ratings for GSK and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding GSK and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
